Stock NKTX NKARTA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Nkarta, Inc.

Equities

NKTX

US65487U1088

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
6.51 USD +0.70% Intraday chart for Nkarta, Inc. +25.68% -1.36%
Jun. 27 Nkarta Initiates Trial of Cell Therapy to Treat Lupus Nephritis; FDA Clears Second Application MT
Jun. 27 Nkarta, Inc. Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Nkarta Initiates Trial of Cell Therapy to Treat Lupus Nephritis; FDA Clears Second Application
MT
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
AQ
Nkarta, Inc. Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
CI
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
AQ
Nkarta, Inc. Appoints George Vratsanos as Board of Directors
CI
Certain Common Stock of Nkarta, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.
CI
Certain Pre-Funded Warrants of Nkarta, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.
CI
Certain Stock Options of Nkarta, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.
CI
Nkarta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
AQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
BU
Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
BU
The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
BU
Nkarta to Participate in Upcoming Investor Conferences
AQ
Canaccord Genuity Adjusts Nkarta's Price Target to $16 From $15, Keeps Buy Rating
MT
HC Wainwright Adjusts Price Target on Nkarta to $22 From $20, Keeps Buy Rating
MT
Nkarta Prices $240.1 Million Underwritten Offering
MT
Nkarta Announces Pricing of $240 Million Underwritten Offering
AQ
North American Morning Briefing : Tech in Focus on -2-
DJ
Mizuho Securities Lowers Price Target on Nkarta to $25 From $31, Keeps Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NKTX Stock
  4. News Nkarta, Inc.